岸迈生物科技（苏州）有限公司

EpimAb Biotherapeutics is an emerging innovative international biotechnology enterprise, focusing on the process development and production of innovative biopharmaceuticals by using the bispecific antibody technology platform (FIT-Ig®) which owns independent intellectual property rights.
FIT-Ig® ss a new bispecific antibody technology platform, which can connect two antibodies together to form bispecific antibody by simple molecular biological means. The bispecific antibody has the function of two original antibodies at the same time, with dual activity and industrialization advantages. Based on FIT-Ig® platform technology, the headquarter Shanghai EpimAb Biotherapeutics Co., Ltd. has more than ten first-in-class biological macromolecular new drug R&D projects independently developed, focusing on cancer targeted therapy, tumor immunity, T cell oriented therapy and other fields. Among them, one product is in the stage of clinical trials in China and the United States, and others are in the stage of preclinical development.
EpimAb Biotherapeutics (Suzhou) Co., Ltd. undertakes the process development and clinical sample production activities of new products from Shanghai headquarter, including a cell line development, upstream and downstream and formulation laboratory, a 200L pilot production line, a 200x500L GMP stock solution production line, an automatic DP production line for washing, pouring, sealing and rolling, and corresponding QC laboratory and utility system. More than 50 batches of preclinical and clinical samples can be produced every year.